Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dibenzepin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 5/20 | 0.97 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.97 |
| ▸ | DRD2 | P14416 | 4/20 | 0.97 |
| ▸ | HTR6 | P50406 | 4/20 | 0.97 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.97 |
| ▸ | HTR1A | P08908 | 3/20 | 0.97 |
| ▸ | HTR2A | P28223 | 3/20 | 0.97 |
| ▸ | HTR7 | P34969 | 2/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.97 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.97 |
| ▸ | MAPT | P10636 | 1/20 | 0.97 |
| ▸ | DRD1 | P21728 | 1/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.97 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.97 |
| ▸ | DRD3 | P35462 | 1/20 | 0.97 |
| ▸ | HEXA | P06865 | 1/20 | 0.54 |
| ▸ | HEXB | P07686 | 1/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dibenzepin SCHEMBL29375228 | 1.00 | HRH1 (0.97) | HRH1DRD2HTR6SLC6A4HTR1A | |
| Dibenzepin SCHEMBL29354805 | 0.98 | HRH1 (1.00) | HRH1DRD2HTR6SLC6A4HTR1A | |
| Dibenzepin SCHEMBL49286 | 0.98 | HRH1 (1.00) | HRH1DRD2HTR6SLC6A4HTR1A | |
| Dibenzepin SCHEMBL14973430 | 0.95 | HRH1 (0.94) | HRH1DRD2HTR6SLC6A4HTR1A | |
| Dimetacrine SCHEMBL28221926 | 0.83 | HRH1 (0.71) | HRH1DRD2HTR6SLC6A4HTR1A | |
| SCHEMBL11746213 | 0.83 | HRH1 (0.72) | HRH1DRD2HTR6SLC6A4HTR1A | |
| Hydrochloric Acid SCHEMBL27677276 | 0.82 | HEXA (0.70) | HRH1DRD2HTR6SLC6A4HTR1A | |
| SCHEMBL29492639 | 0.81 | HRH1 (0.69) | HRH1DRD2HTR6SLC6A4HTR1A | |
| Hydrochloric Acid SCHEMBL9397346 | 0.81 | DRD2 (0.70) | HRH1DRD2HTR6SLC6A4HTR1A | |
| Dibenzepin SCHEMBL28086113 | 0.81 | HRH1 (0.68) | HRH1DRD2HTR6SLC6A4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 270 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240307386-A1 | NOVEL METHODS | INTRA-CELLULAR THERAPIES, INC. | 2024-09-19 | — | — | US | claimed |
| US-20230381168-A1 | ADJUNCTIVE THERAPY FOR DEPRESSION | ANEUROTECH BV (BE) | 2023-11-30 | — | — | US | claimed |
| EP-3801527-A1 | NOVEL METHODS | Intra-Cellular Therapies, Inc. (US) | 2021-04-14 | — | — | EP | claimed |
| US-20210060009-A1 | NOVEL METHODS | INTRA-CELLULAR THERAPIES, INC. | 2021-03-04 | — | — | US | claimed |
| EP-3765021-A1 | NOVEL METHODS | Intra-Cellular Therapies, Inc. (US) | 2021-01-20 | — | — | EP | claimed |
| US-20200038420-A1 | AMINOSTEROL COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATING DEPRESSION | ENTERIN, INC. (US) | 2020-02-06 | — | — | US | claimed |
| WO-2019178484-A1 | NOVEL METHODS | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-09-19 | — | — | WO | claimed |
| US-12605333-B2 | Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release | TRIS PHARMA, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260098052-A1 | HUMAN AMINOSTEROL ENT-03 COMPOUNDS, RELATED COMPOSITIONS COMPRISING THE SAME, AND METHODS OF USING THE SAME | ENTERIN, INC. (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260096986-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A FLOATING INTERPENETRATING POLYMER NETWORK FORMING SYSTEM | TRIS PHARMA INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260053748-A1 | NOVEL METHODS | INTRA CELLULAR THERAPIES INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-20260041667-A1 | PRESCRIPTION DIGITAL THERAPEUTICS | BECKLEY PSYTECH LTD (GB) | 2026-02-12 | — | — | US | disclosed |
| US-20260035334-A1 | METHOD OF SYNTHESIS | BECKLEY PSYTECH LTD (GB) | 2026-02-05 | — | — | US | disclosed |
| US-20040220262-A1 | Transdermal and topical administration of drugs using basic permeation enhancers | TECHNOLOGY RECOVERY SYSTEMS, LLC | 2004-11-04 | — | — | US | disclosed |
| US-20030124176-A1 | Transdermal and topical administration of drugs using basic permeation enhancers | DERMATRENDS, INC. | 2003-07-03 | — | — | US | disclosed |
| US-20030104041-A1 | Transdermal and topical administration of drugs using basic permeation enhancers | DERMATRENDS, INC. | 2003-06-05 | — | — | US | disclosed |
| US-20020192302-A1 | Transdermal and topical administration of antidepressant drugs using basic enhancers | DERMATRENDS, INC. | 2002-12-19 | — | — | US | disclosed |
| CN-1224366-A | Pharmaceutical administration form | MUELLER D (DE) | 1999-07-28 | — | — | CN | disclosed |
| EP-0907388-A1 | PHARMACEUTICAL ADMINISTRATION FORM | Müller, Dieter (DE) | 1999-04-14 | — | — | EP | disclosed |
| WO-1998000198-A1 | PHARMACEUTICAL ADMINISTRATION FORM | MUELLER DIETER (DE) | 1998-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210060009-A1 | NOVEL METHODS | HTR2A, HTR3B, HTR1A | HRH1 293/4885SLC6A2 182/4885DRD2 100/4885 |
| US-20260096986-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A FLOATING INTERPENETRATING POLYMER NETWORK FORMING SYSTEM | SI, FABP2, FABP6 | HRH1 1139/4885SLC6A2 841/4885DRD2 3531/4885 |
| US-12605333-B2 | Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release | SI, GRPR, FABP2 | HRH1 82/4885SLC6A2 1163/4885DRD2 3220/4885 |
| US-20200038420-A1 | AMINOSTEROL COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATING DEPRESSION | HSD17B7, CYP17A1, HSD17B2 | HRH1 3183/4885SLC6A2 101/4885DRD2 1735/4885 |
| US-20260053748-A1 | NOVEL METHODS | HTR1D, HTR2C, HTR1A | HRH1 71/4885SLC6A2 29/4885DRD2 18/4885 |
| US-20240307386-A1 | NOVEL METHODS | OPRL1, HTR2A, OPRM1 | HRH1 701/4885SLC6A2 174/4885DRD2 58/4885 |
| US-20260035334-A1 | METHOD OF SYNTHESIS | HTR5A, HTR1A, HTR2C | HRH1 1041/4885SLC6A2 11/4885DRD2 77/4885 |
| US-20230381168-A1 | ADJUNCTIVE THERAPY FOR DEPRESSION | HTR2A, HTR3B, HTR5A | HRH1 255/4885SLC6A2 44/4885DRD2 11/4885 |
| US-20260098052-A1 | HUMAN AMINOSTEROL ENT-03 COMPOUNDS, RELATED COMPOSITIONS COMPRISING THE SAME, AND METHODS OF USING THE SAME | HSD3B1, HSD3B2, HSD11B1 | HRH1 1090/4885SLC6A2 1842/4885DRD2 1158/4885 |
| US-20260041667-A1 | PRESCRIPTION DIGITAL THERAPEUTICS | HTR5A, PNMT, NPY5R | HRH1 1667/4885SLC6A2 9/4885DRD2 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.